Administration of the peroxisomal proliferator-activated receptor γ agonist pioglitazone during fractionated brain irradiation prevents radiation-induced cognitive impairment

Conclusions: These findings offer the promise of improving the quality of life and increasing the therapeutic window for brain tumor patients.